Intensity Therapeutics GAAP EPS of -$0.13

* Intensity Therapeutics press release [https://seekingalpha.com/pr/20194119-intensity-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate] (NASDAQ:INTS [https://seekingalpha.com/symbol/INTS]): Q2 GAAP EPS of -$0.13.
* Over $11 million raised since the beginning of 2Q 2025
* Cash runway extended into the second half of 2026
* In the INVINCIBLE-4 Study, patients receiving INT230-6 prior to the start of standard of care achieved high levels of tumor necrosis in 8 days
* INT230-6 achieved 100% complete response rate in preclinical models of malignant peripheral nerve sheath tumors
* Shares +3.85% AH.

MORE ON INTENSITY THERAPEUTICS

* Intensify Therapeutics slumps 27%, prices $2M stock offering [https://seekingalpha.com/news/4457489-intensify-therapeutics-slumps-27-prices-2m-stock-offering]
* Seeking Alpha’s Quant Rating on Intensity Therapeutics [https://seekingalpha.com/symbol/INTS/ratings/quant-ratings]
* Historical earnings data for Intensity Therapeutics [https://seekingalpha.com/symbol/INTS/earnings]
* Financial information for Intensity Therapeutics [https://seekingalpha.com/symbol/INTS/income-statement]